Entering text into the input field will update the search result below

Roche lung-cancer drug suffers major blow in Phase III trial

Mar. 03, 2014 3:30 AM ETRoche Holding AG (RHHBY) StockRHHBY, RHHBFBy: Yigal Grayeff, SA News Editor
  • An independent committee has recommended that Roche (OTCQX:RHHBY) end a Phase III trial of its MetMab (Onartuzumab) lung-cancer treatment, as the drug didn't show "clinically meaningful efficacy."
  • The aim of the study was to assess whether Onartuzumab, when given with the oral therapy Tarceva, helped previously treated patients live longer compared with those who just received Tarceva.
  • Analysts had viewed MetMab as a potential blockbuster and Roche is analyzing what the setback means for the drug's development.
  • Shares are -1.7% in Zurich. (PR)

Recommended For You

More Trending News

About RHHBY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RHHBY--
Roche Holding AG